MK-0941, a novel glucokinase activator (GKA), lowers HbA1c in type 2 diabetes (T2DM) but lacks glycaemic durability

被引：0
|
作者：
Meininger, G. E. [1 ]
Shentu, Y. [1 ]
Chen, Y. [1 ]
Yu, Q. [1 ]
Sheng, D. [1 ]
Musser, B. J. [1 ]
Alba, M. [1 ]
Zhang, B. B. [1 ]
Migoya, E. M. [1 ]
Ehrhart, J. [1 ]
Kaufman, K. D. [1 ]
Goldstein, B. J. [1 ]
机构：
[1] Merck, Rahway, NJ USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
242
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [1] The Hepatoselective Glucokinase Activator (GKA) PF-04991532, Lowers HbA1c after 12-Weeks of Dosing in Patients With Type 2 Diabetes (T2DM)
    Kazierad, David J.
    Pfefferkorn, Jeffrey A.
    Bergman, Arthur
    Wang, Xin
    Rolph, Timothy P.
    Rusnak, James M.
    [J]. DIABETES, 2013, 62 : A271 - A271
  • [2] Glucose-Lowering Effects of an Oral Glucokinase (GK) Activator, MK-0941, in Patients with Type 2 Diabetes (T2DM) Inadequately Controlled by Metformin
    O'Neill, Edward A.
    Migoya, Elizabeth
    Miller, Jutta
    Moreau, Meghan
    Maganti, Lata
    Larson, Patrick
    Gutierrez, Maria
    Denoia, Emanuel
    Wagner, John A.
    Stoch, Aubrey
    [J]. DIABETES, 2011, 60 : A608 - A608
  • [3] Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
    Meininger, Gary E.
    Scott, Russell
    Alba, Maria
    Yue Shentu
    Luo, Edmund
    Amin, Himal
    Davies, Michael J.
    Kaufman, Keith D.
    Goldstein, Barry J.
    [J]. DIABETES CARE, 2011, 34 (12) : 2560 - 2566
  • [4] Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs
    Eiki, Jun-ichi
    Nagata, Yasufumi
    Futamura, Mayumi
    Sasaki-Yamamoto, Kaori
    Iino, Tomoharu
    Nishimura, Teruyuki
    Chiba, Masato
    Ohyama, Sumika
    Yoshida-Yoshimioto, Riki
    Fujii, Kenji
    Hosaka, Hideka
    Goto-Shimazaki, Hiroko
    Kadotani, Akito
    Ohe, Tomoyuki
    Lin, Songnian
    Langdon, Ronald B.
    Berger, Joel P.
    [J]. MOLECULAR PHARMACOLOGY, 2011, 80 (06) : 1156 - 1165
  • [5] HbA1c and Prediction of Type 2 Diabetes (T2DM) in Children and Adults
    Vijayakumar, Pavithra
    Nelson, Robert G.
    Hanson, Robert L.
    Knowler, William C.
    Sinha, Madhumita
    [J]. DIABETES, 2016, 65 : A65 - A65
  • [6] Modelling HbA1c Trajectory in Patients with Type 2 Diabetes Mellitus (T2DM)
    Mcewan, Phil
    Fellows, Jonathan
    Yapp, Rhiannon
    Bergenheim, Klas
    Qin, Lei
    Varol, Nebibe
    Bennett, Hayley
    Gordon, Jason
    [J]. DIABETES, 2016, 65 : A322 - A322
  • [7] Clustering of HBA1C longitudinal trajectories in type 2 diabetes mellitus (T2DM)
    De la Torre, Adrian Martinez
    Faquetti, Maria Luisa Marques De Sa
    Perez-Cruz, Fernando
    Weiler, Stefan
    Burden, Andrea
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 60 - 60
  • [8] LY2599506, a Novel Glucokinase Activator (GKA), Improves Fasting and Postprandial Glucose in Patients with Type 2 Diabetes Mellitus (T2DM)
    Bue-Valleskey, Juliana M.
    Schneck, Karen B.
    Sinha, Vikram P.
    Wondmagegnehu, Eshetu T.
    Kapitza, Christoph
    Miller, Jeffrey W.
    [J]. DIABETES, 2011, 60 : A272 - A272
  • [9] Treatment Progression and Impact of HbA1C in Type 2 Diabetes (T2DM) Patients
    Dibello, Julia R.
    Levy, Brian
    Mehra, Maneesha
    [J]. DIABETES, 2010, 59 : A623 - A624
  • [10] Additional Glucose-Lowering Effects of the Oral GK Activator, MK-0941, in Patients with T2DM on Basal Insulin
    Migoya, Elizabeth
    Miller, Jutta
    Moreau, Meghan
    Reitman, Christina
    Maganti, Lata
    Larson, Patrick
    Gutierrez, Maria
    Morrow, Linda
    Denoia, Emanuel
    Gottesdiener, Keith
    Wagner, John A.
    [J]. DIABETES, 2011, 60 : A595 - A595
12345